TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 088/02376		
In Re Application Of: Amir LOSHAKOVE, et al.							
Application No.		Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
09/936,806		September 17, 2001	O' CONNOR, C. E.	44909	3732	9502	
Title: VASCULAR SURGERY							
Address to:  Commissioner for Patents  P.O. Box 1450  Alexandria, VA 22313-1450							
37 CFR 1.97(b)							
1.	of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
2. 🗵	CFR 1.97( Final Action	The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
	☐ the statement specified in 37 CFR 1.97(e);						
	OR						
	⊠ the f	fee set forth in 37 CF	R 1.17(p).				

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) 088/02376 In Re Application: Amir LOSHAKOVE, et al. Application No. Filing Date Examiner Customer No. Group Art Unit Confirmation No. 09/936,806 9502 September 17, 2001 O' CONNOR, C. E. 44909 3732 Title: VASCULAR SURGERY Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. ☑ The Director is hereby authorized to charge and credit Deposit Account No. 03-3419 as described below. Charge the amount of \$180.00 X Credit any overpayment. X Charge any additional fee required. Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Transmission by Facsimile\* Certificate of Mailing by First Class Mail I hereby certify that this correspondence is being deposited I certify that this document and authorization to charge deposit with the United States Postal Service with sufficient postage account is being facsimile transmitted to the United States as first class mail in an envelope addressed to Patent and Trademark Office (Fax. No. "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on (Date) (Date) Signature of Person Mailing Correspondence Signature Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate \*This certificate may only be used if paying by deposit account. Dated: June 14, 2005 Signature Maier Fenster, Reg. No. 41,016 William H. Dippert, Esq. Wolf, Block, Schorr & Solis-Cohen LLP 250 Park Avenue New York, New York 10177 Tel: (212) 986 1116 CC:

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regard to the application of: Amir LOSHAKOVE, et al.

Serial No: 09/936,806

Group Art Unit: 3732

Filed

September 17, 2001

Examiner: O' CONNOR, C. E.

For

VASCULAR SURGERY

## TENTH SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants respectfully direct the attention of the Examiner to additional art cited with respect to U.S. Application No. 09/936,806 which is a U.S. National Phase of PCT Application No. PCT/IL99/00670, which is a Continuation-in-part of U.S. Application No. 09/701,531, and of U.S. Application No. 09/701,523.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP 2001.06, MPEP 1893.03(e) and MPEP 1893.03(g) and to indicate in the next office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 C.F.R. §1.97 and §1.98, attached is an Equivalent to Form PTO-1449 listing the cited art. Also attached are copies of the art. This art contains information which the examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

Applicants point out that items 12-43 listed on the attached 1449 Form were cited by applicants in a previous IDS and are being resubmitted along with a copy of each reference in

To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the national stage file. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited then none is known to the undersigned.

order to overcome the Examiner's objection to the IDS noted in the Office Action dated November 30, 2004 issued for the present application.

In accordance with MPEP Section 609 it is requested that each document cited (including any mentioned in Applicant's specification which is not repeated on the attached PTO-1449 form or equivalent) be given thorough consideration and be cited of record in the prosecution history of the present application by initialing on the PTO-1449 form or its equivalent, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 C.F.R. §1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 C.F.R. §1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted, Amir LOSHAKOVE et al.

Maier FENSTER,

Registration No. 41,016

June 14, 2005

William H. Dippert, Esq. Wolf, Block, Schorr & Solis-Cohen LLP 250 Park Avenue New York, New York 10177.

Tel: (212) 986 1116